Hitachi Chemical Company, Ltd.

Hitachi Chemical Research Center, Inc.

Hitachi Chemical Company America, Ltd.

Other

City of Sapporo

Hitachi, Ltd.

University of California

The Cleveland Clinic Foundation

City of Hope

Cedars-sinai Medical Center

Beth Israel Deaconess Medical Center, Inc.

Showa Denko Materials Co., Ltd.

Showa Denko Materials (america), Inc.

Shin Yokohama Kato Clinic

Masato Mitsuhashi

Taku Murakami

Mieko Ogura

Hideki Kambara

Allan J Cooper

Hiroshi Harada

Tatsuo Akitaya

Stephan R Targan

Hiroshi Izutsu

Kazuhiko Obara

Yoko Mullen

Charles Y Chu

Hiroko Matsunaga

Cindy M Yamamoto

Michael S Waterman

Ravindra Lall Mehta

Masafumi Kawamura

Mina Okochi

Masafumi Yohda

Katsuya Endo

Alan C Moss

Shuji Ohta

Tsuruki Tamura

Keiko Omori

Yoichi Agata

Ernest C Borden

Pavel A Pevzner

Cylia Keller

Satish P RamachandraRao

Kenji Watanabe

Jifan Li

Melanie Oakes

Yoichi Kato

Kumar Sharma

The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various urothelial cancers. In particular, various expression patterns are analyzed through a unique diagnostic formula.

Molecular methods for assessing urothelial disease

Provided herein are devices and methods for the capture or isolation of a biomarker from a biological sample. In several embodiments, the device comprises a loading region, a filter material, and a receiving region. In particular, in several embodiments, biological fluid is passed from the loading region through the filter material and into the receiving region, thereby resulting in capture or isolation of a biomarker.

Devices and methods for capturing target molecules

Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.

Portable device for ex vivo stimulation of whole blood

The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine and isolating corresponding mRNA in order to diagnose and treat acute kidney injury (AKI). In particular, certain embodiments relate to the method of capturing EMV from urine applied to a filter device that is capable of capturing EMV. Nucleic acids such as mRNA can be isolated from the EMV using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of IBD.

Method and device for diagnosing organ injury

The present disclosure relates to methods of collecting intestinal luminal fluid (ILF) exosomes and microvesicles (EMV) and isolating corresponding mRNA in order to diagnose and treat inflammatory bowel diseases (IBD). In particular, certain embodiments relate to the method of capturing EMV from ILF applied to a filter device that is capable of capturing EMV. Nucleic acids such as mRNA can be isolated from the EMV using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of IBD.

Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease

Some embodiments provide for a device that collects vesicles and vesicle-like materials from biological fluids. Such devices include at least one sample loading region; at least one corresponding vesicle-capture material, wherein said vesicle-capture material includes glass-like materials; and at least one corresponding sample receiving region, wherein passage of the biological fluid from the sample loading region through the vesicle-capture material and into the sample receiving region results in the capture of vesicles. Additional embodiments provide for a method of isolating vesicles and vesicle-like materials from biological fluids.

Methods for isolation of biomarkers from vesicles

p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-&#x3b1; stimulation in a time- and dose-dependent manner and &#x3b2; cell apoptosis is induced through a mitochondrial pathway. TNF-&#x3b1; significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such &#x3b2; cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.

PUMA, a pro-apoptotic gene, as a novel molecular biomarker for TNF&#x3b1;-induced human islet damage

Provided is a device that collects vesicles and vesicle-like materials from biological fluids. Such devices comprise at least one sample loading region; at least one corresponding vesicle-capture material, wherein said vesicle-capture material comprises glass-like materials; and at least one corresponding sample receiving region, wherein passage of the biological fluid from the sample loading region through the vesicle capture material and into the sample receiving region results in the capture of vesicles. Additional methods provide for a method of isolating vesicles and vesicle-like materials from biological fluids are also provided.

Methods for isolating vesicles from biological fluids

Embodiments of the invention relate generally to methods of diagnosing diseases and measuring homeostatic states. In particular, the methods described here are used to characterize RNA from vesicles for expression of disease related markers. Embodiments of the invention also relate generally to the characterization of RNA by using sensitive techniques such as PCR to internally sample organ health using whole blood.

Method of characterizing vascular diseases

Embodiments of the invention relate generally to ex vivo methods of quantifying expression of interferon responsive genes and characterizing an individual's potential responsiveness to interferon administration. Certain embodiments relate to methods to monitor the efficacy of ongoing interferon therapy by evaluating expression of interferon responsive genes before and after interferon administration.

Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers

Embodiments of the invention relate generally to methods of characterizing kidney function. In particular, several embodiments quantify kidney-associated marker RNA isolated from vesicles contained in patient urine samples. In some embodiments, the quantified RNA from urine vesicles is compared to a normal population and in some embodiments is compared to the patient to evaluate kidney function over time.

Methods for characterizing kidney function

A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily ('TNFSF')-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.

Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis

Provided herein are primer/probe sets useful for detecting HIV (HIV-1) in a test sample. The primer/probe sets can be employed according to nucleic acid amplification procedures including PCR, real-time quantitative PCR, or RT-PCR. The primer/probe sets can also be provided in the form of a kit with other reagents for performing a nucleic acid amplification reaction.

Primers and probes for the detection of HIV

Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Device and method for high-throughput quantification of mRNA from whole blood

Growing community of inventors

Irvine, CA, United States of America

Masato Mitsuhashi